Insulin resistance in patients with hypertrophic cardiomyopthy

Circulation Journal

Volumn 68, Issue 7, 2004, Pages 650-655

  Murakami, Kazuo ^a   Shigematsu, Yuji ^b   Hamada, Mareomi ^c   Higaki, Jitsuo ^b  

^a MATSUYAMA RED CROSS HOSPITAL   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Uwajima City Hospital   (Japan)

Author keywords

Hypertrophic cardiomyopathy; Insulin resistance; Left ventricular hypertrophy; Prognosis

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM DEFECT; HOMEOSTASIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROVOCATION; SUDDEN DEATH;

BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOMYOPATHY, HYPERTROPHIC; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROGNOSIS; REFERENCE VALUES; SURVIVAL ANALYSIS;

EID: 3142766836     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.650     Document Type: Article

References (39)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
3. Devereux RB, de Simone G, Pickering TG, Schwartz JE, Roman MJ. Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension 1998; 31: 929-936.
4. Hill DJ, Millner DG. Insulin as a growth factor. Pediatr Res 1985; 19: 879-886.
5. Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Ahichiri M, et al. Insulin-like growth factor-1 induces cardiac hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993; 87: 1715-1721.
6. Lind L, Andersson PE, Andren B, Hanni A, Lithell HO. Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. J Hypertens 1995; 13: 433-438.
7. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58-60.
8. Li R-K, Li G, Mickle DAG, Weisel RD, Merante F, Luss H, et al. Overexpression of transforming growth factor-beta 1 and insulin-like growth factor-I in patients with idiopathic hypertyrophic cardiomyopathy. Circulation 1997; 96: 874-881.
9. Li G, Li R-K, Mickle DAG, Weisel RD, Merante F, Ball WT, et al. Elevated insulin-like growth factor-I and transforming growth factor-beta1 and their receptors in patients with idiopathic hypertyrophic obstructive cardiomyopathy. Circulation 1998; 98: II-144-II-150.
10. Saeki H, Hamada M, Hiwada K. Circulating levels of insulin-like growth factor-1 and its binding proteins in patients with hypertrophic cardiomyopathy. Circ J 2002; 66: 639-644.
11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
12. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-842.
13. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug Cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524.
14. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, sumimoto T, Hiwada K. Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens 1995; 13: 155-160.
15. National High Blood Pressure Education Program; US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.
17. Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. Jpn Circ J 1995; 59: 329-336.
18. Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-Mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613-618.
20. Reichek N, Devereux RB. Reliable estimation of peak left ventricular systolic pressure by M-mode echographic-determined end-diastolic relative wall thickness: Identification of severe valvular aortic stenosis in adult patients. Am Heart J 1982; 103: 202-209.
21. Sasson Z, Yock PG, Hatle LK, Alderman EL, Popp RL. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11: 752-756.
22. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension: A meta-analysis. Arch Intern Med 1992; 152: 1649-1651.
23. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorder: The Bruneck Study. Diabetes 1998; 47: 1643-1649.
24. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999; 42: 246-253.
25. Strauss DS. Growth-stimulatory actions of insulin in vitro and in vivo. Endocr Rev 1984; 5: 356-367.
26. Hara-Nakamura N, Kohara K, Sumimoto T, Lin M, Hiwada K. Glucose intolerance exaggerates left ventricular hypertrophy and dysfunction in essential hypertension. Am J Hypertens 1994; 7: 1110-1114.
27. Verdecchia P, Reboldi G, Schillaci G, Borgioni C, Ciucci A, Telera MP, et al. Circulating insulin and insulin insulin-like growth factor-1 are independent determinants of left ventricular mass and geometry in essential hypertension. Circulation 1999; 100: 1802-1807.
28. Swislocki ALM, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in a patients with hypertension. Am J Hypertens 1989; 49: 419-423.
29. 2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 1998; 275: C200-C207.
30. Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res 1998; 82: 106-115.
31. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215-228.
32. Hallak H, Ramadan B, Rubin R. Tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) by oxidant stress in cerebellar granule neurons: Modulation by N-methyl-D-aspartate through calcineurin activity. J Neurochem 2001; 77: 63-70.
33. Naya FJ, Mercer B, Shelton J, Richardson JA, Williams RS, Olson EN. Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 2000; 275: 4545-4548.
34. Cuda G, Fananapazir L, Epstein ND, Sellers JR. The in vivo motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy-chain gene mutation in hypertrophic cardiomyopathy. J Muscle Res Cell Motil 1997; 18: 1-9.
35. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 1999; 400: 581-585.
36. 2+ dependent calcineurin signalling pathway. Nature 1999; 400: 576-581.
37. Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-655.
38. Hecht GM, Klues HG, Roberts WC, Maron BJ. Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22: 489-497.
39. Hara Y, Hamada M, Shigematsu Y, Ohtsuka T, Ogimoto A, Higaki J. Effect of beta-blockers on insulin resistance in patients with dilated cardiomyopathy. Circ J 2003; 67: 701-704.